Literature DB >> 4016960

Immunization of susceptible BALB/c mice against Leishmania braziliensis. II. Use of temperature-sensitive avirulent clones of parasite for vaccination purposes.

R M Gorczynski.   

Abstract

Avirulent clones of Leishmania braziliensis were produced by treatment of parental parasite stock with the mutagen N-methyl-N'-methyl-N'-nitro-N-nitrosoguanidine and selection for growth at 19 degrees C. These clones have a clear preference for infection and growth in vitro at 19 degrees C rather than the normal 28 degrees C. In addition, they can be used to vaccinate naive mice successfully against growth of the parental parasite clones. Immunity can be adoptively transferred from vaccinated mice by Lyt-1+ cells from immunized animals.

Entities:  

Mesh:

Year:  1985        PMID: 4016960     DOI: 10.1016/0008-8749(85)90081-4

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  14 in total

1.  Effect of neonatal injection with antibodies to Leishmania mexicana on its growth in adult infected mice.

Authors:  R M Gorczynski
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

Review 2.  Identifying vaccine targets for anti-leishmanial vaccine development.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Rev Vaccines       Date:  2014-04       Impact factor: 5.217

3.  Vaccines for leishmaniasis and the implications of their development for American tegumentary leishmaniasis.

Authors:  Beatriz Coutinho De Oliveira; Malcolm S Duthie; Valéria Rêgo Alves Pereira
Journal:  Hum Vaccin Immunother       Date:  2019-11-11       Impact factor: 3.452

4.  Altered virulence and vaccination properties of Leishmania parasites grown in infected vaccinated mice.

Authors:  R M Gorczynski
Journal:  Infect Immun       Date:  1989-08       Impact factor: 3.441

5.  Therapeutic immunization with radio-attenuated Leishmania parasites through i.m. route revealed protection against the experimental murine visceral leishmaniasis.

Authors:  Sanchita Datta; Madhumita Manna; Supriya Khanra; Moumita Ghosh; Radhaballav Bhar; Anindita Chakraborty; Syamal Roy
Journal:  Parasitol Res       Date:  2012-03-23       Impact factor: 2.383

6.  Development of Vaccines against Visceral Leishmaniasis.

Authors:  Krystal J Evans; Lukasz Kedzierski
Journal:  J Trop Med       Date:  2011-09-05

Review 7.  The History of Live Attenuated Centrin Gene-Deleted Leishmania Vaccine Candidates.

Authors:  Greta Volpedo; Parna Bhattacharya; Sreenivas Gannavaram; Thalia Pacheco-Fernandez; Timur Oljuskin; Ranadhir Dey; Abhay R Satoskar; Hira L Nakhasi
Journal:  Pathogens       Date:  2022-04-02

8.  Leishmania donovani whole cell antigen delivered with adjuvants protects against visceral leishmaniasis in vervet monkeys (Chlorocebus aethiops).

Authors:  Joshua Muli Mutiso; John Chege Macharia; Evans Taracha; Michael Muita Gicheru
Journal:  J Biomed Res       Date:  2012-01

9.  Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis.

Authors:  Noushin Saljoughian; Tahereh Taheri; Farnaz Zahedifard; Yasaman Taslimi; Fatemeh Doustdari; Azam Bolhassani; Delaram Doroud; Hiva Azizi; Kazem Heidari; Mohammad Vasei; Nabiollah Namvar Asl; Barbara Papadopoulou; Sima Rafati
Journal:  PLoS Negl Trop Dis       Date:  2013-04-18

Review 10.  Live vaccination tactics: possible approaches for controlling visceral leishmaniasis.

Authors:  Noushin Saljoughian; Tahareh Taheri; Sima Rafati
Journal:  Front Immunol       Date:  2014-03-31       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.